Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 2/20 | 0.37 |
| ▸ | ADH1B | P00325 | 1/20 | 0.37 |
| ▸ | ADH1C | P00326 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13397397 | 0.90 | DRD2 (0.32) | DRD2DRD3 | |
| SCHEMBL7201658 | 0.88 | ADH1A (0.39) | ADH1AADH1BADH1CEPHX1DRD2 | |
| SCHEMBL4382413 | 0.86 | ADH1A (0.36) | ADH1AADH1BADH1CDRD2DRD3 | |
| SCHEMBL39288 | 0.82 | ADH1A (0.40) | ADH1AADH1BADH1CDRD2DRD3 | |
| SCHEMBL1674463 | 0.82 | SIGMAR1 (0.32) | ADH1AADH1BADH1CSIGMAR1 | |
| SCHEMBL28083249 | 0.81 | ADH1A (0.39) | ADH1AADH1BADH1CSIGMAR1EPHX1 | |
| SCHEMBL735434 | 0.81 | ADH1A (0.37) | ADH1AADH1BADH1C | |
| SCHEMBL27420655 | 0.81 | ADH1A (0.37) | ADH1AADH1BADH1C | |
| SCHEMBL736907 | 0.78 | ADH1B (0.34) | ADH1AADH1BADH1C | |
| SCHEMBL17914487 | 0.78 | ADH1A (0.47) | ADH1AADH1BADH1CDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7301037-B2 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070105135-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105135-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | POLRMT, PCNA, SARS1 | ADH1A 4677/4885ADH1B 3364/4885ADH1C 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.